Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-28 4:03 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | Octagon Capital Advisors LP | 225,000 1.800% | 225,000 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | AlloVir, Inc. ALVR | Octagon Capital Advisors LP | 11,202,000 9.700% | 11,202,000 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Octagon Capital Advisors LP | 1,976,387 5.900% | 1,976,387 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Octagon Capital Advisors LP | 1,115,000 9.300% | 1,115,000 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | Octagon Capital Advisors LP | 1,746,667 6.000% | 1,746,667 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Regulus Therapeutics Inc. RGLS | Octagon Capital Advisors LP | 4,263,701 6.500% | 4,263,701 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY | Octagon Capital Advisors LP | 8,559,000 9.100% | 8,559,000 (New Position) | Filing History |
| 2024-08-28 4:02 pm Sale | 2024-08-26 | 13G | AN2 Therapeutics, Inc. ANTX | Octagon Capital Advisors LP | 0 0.000% | -3,009,927 (Position Closed) | Filing History |
| 2024-07-03 08:02 am Purchase | 2024-06-13 | 13G | AN2 Therapeutics, Inc. ANTX | Octagon Capital Advisors LP | 3,009,927 10.100% | 3,009,927 (New Position) | Filing History |
| 2024-02-06 4:04 pm Sale | 2024-01-02 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 0 0.000% | -1,785,000 (Position Closed) | Filing History |
| 2024-02-05 4:01 pm Purchase | 2023-12-31 | 13G | Reneo Pharmaceuticals, Inc. RPHM | Octagon Capital Advisors LP | 225,000 6.750% | 225,000 (New Position) | Filing History |
| 2024-02-05 4:01 pm Sale | 2023-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 1,785,000 6.480% | -640,000 (-26.39%) | Filing History |
| 2023-01-25 4:01 pm Purchase | 2022-12-31 | 13G | Xilio Therapeutics, Inc. XLO | Octagon Capital Advisors LP | 2,425,000 8.830% | 2,425,000 (New Position) | Filing History |